Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes. The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects With Acute Coronary Syndrome)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Thienopyridines
- Indications Acute coronary syndromes; Cardiovascular disorders; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms ATLAS-ACS-TIMI-46
- Sponsors Bayer
- 18 Nov 2019 Results (N= 1282), post-hoc analysis to assess the link between WBC count and bleeding in patients on Rivaroxaban, presented at the American Heart Association Scientific Sessions 2019
- 14 Nov 2018 Results assessing the association between D-Dimer Levels and Clinical Outcomes in Acute Coronary Syndrome Patients (n=1,834) presented at the 91st Annual Scientific Sessions of the American Heart Association
- 04 Aug 2018 Results of a substudy in a subset of subjects (n =1834) assessing the D-dimer levels and the effect of Rivaroxaban on those levels and outcomes in patients with acute coronary syndrome, published in the American Journal of Cardiology.